drugset / Trial / NCT02377752
A Study of Olaratumab in Japanese Participants With Advanced Cancer
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This study consists of 2 parts (Part A and Part B). The main purpose of Part A is to evaluate safety and side effects of olaratumab in combination with doxorubicin in Japanese participants with a group of rare cancers (advanced solid tumors, especially advanced soft tissue sarcoma \[STS\].) The main purpose of Part B is to evaluate how much olaratumab gets into the blood stream of Japanese participants with advanced solid tumors and how long it takes the body to get rid of it.
Timeline
- Start
- 2015-03-23
- Primary completion
- 2018-08-27
- Completion
- 2020-01-14
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Doxorubicin | Other / unclassified | 25 mg/m2 | Intravenous |
| Subject | Doxorubicin | Other / unclassified | 75 mg/m2 | Intravenous |
| Subject | Olaratumab | Monoclonal antibody | 15 mg/kg | Intravenous |